-
1.发明公开PHARMACEUTICAL COMPOSITION COMPRISING 4-[4[[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYLAMINO]PHENOXY]-N-METHYLPYRIDINE-2-CARBOXAMIDE 审中-公开包含4- [4- [4-氯-3-（三氟甲基）苯基] CARBAMOYLAMIN-]苯氧基] -N-甲基吡啶-2-甲酰胺的药物组合物
公开(公告)号：EP2744484A1
公开(公告)日：2014-06-25
申请号：EP12750726.7
申请日：2012-08-08
申请人： Ratiopharm GmbH
CPC分类号： A61K31/44 , A61K9/2009
摘要： The present invention relates to a pharmaceutical composition having a density of more than 1.55g/cm
3 in the form a tablet comprising 4-[4-[[4-chloro-3-(tifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridin e-2-carboxamide or a pharmaceutically acceptable salt thereof as active agent and at least one pharmaceutically acceptable excipient as well as a method of manufacturing such pharmaceutical composition.-
2.发明公开
公开(公告)号：EP2691395A1
公开(公告)日：2014-02-05
申请号：EP12712846.0
申请日：2012-03-28
申请人： Ratiopharm GmbH
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00
CPC分类号： C07D487/04
摘要： The present invention is directed to Tofacitinib acid addition salts and solid state forms thereof, particularl amorphons tofacitinib acetate, y as well as pharmaceutical compositions comprising one or more of them. The present invention further provides a process for producing Tofacitinib acid addition salt, in particular, Tofacitinib mono citrate salt.
摘要翻译： 本发明涉及Tofacitinib酸加成盐及其固态形式，特别是非索非那醋酸乙酯，以及包含其中一种或多种的药物组合物。 本发明还提供了生产托伐菌素酸加成盐的方法，特别是Tofacitinib单柠檬酸盐。
-
公开(公告)号：EP2451771B1
公开(公告)日：2014-06-18
申请号：EP10731734.9
申请日：2010-07-07
申请人： Ratiopharm GmbH
IPC分类号： C07C211/42 , C07C53/122 , C07C53/126 , C07C57/12 , A61K31/19 , A61K31/13 , A61P25/16
CPC分类号： C07C211/42 , C07C53/122 , C07C53/126 , C07C57/12 , C07C2602/08
-
公开(公告)号：EP2646009A1
公开(公告)日：2013-10-09
申请号：EP11797077.2
申请日：2011-11-29
申请人： Ratiopharm GmbH
发明人： JANSSEN, Christian
IPC分类号： A61K9/70 , A61K31/381 , A61K9/06
CPC分类号： A61K31/381 , A61K9/06 , A61K31/131 , A61K31/19
摘要： The present invention provides ionic liquids of rotigotine, pharmaceutical compositions comprising said ionic liquids and methods of preparing such ionic liquids. The invention further provides methods of using the compositions described herein to overcome problems arising from polymorphism, solubility and delivery, to control release rates, to add functionality, to enhance efficacy, and to improve ease of use and manufacture.
-
公开(公告)号：EP2646008A1
公开(公告)日：2013-10-09
申请号：EP11790776.6
申请日：2011-11-29
申请人： Ratiopharm GmbH
IPC分类号： A61K9/70 , A61K31/381 , A61K31/00
CPC分类号： A61M35/00 , A61K9/7084 , A61K31/381
摘要： The present invention relates to a patch which comprises the active ingredient rotigotine and is intended for transdermal delivery of the active pharmaceutical ingredient rotigotine, comprising a backing layer (1), a matrix layer (2) which comprises the active ingredient, and a removable protective sheet (4) which is intended for removal before the patch is applied to the skin, characterized in that disposed with areal coverage between the matrix layer (2) and the removable protective sheet (4) is an additional interlayer (3).
-
6.发明公开SALTS OF RASAGILINE AND PHARMACEUTICAL PREPARATIONS THEREOF 有权RASAGILIN-SALZE UND PHARMAZEUTISCHE ZUBEREITUNGEN DARAUS
公开(公告)号：EP2451771A1
公开(公告)日：2012-05-16
申请号：EP10731734.9
申请日：2010-07-07
申请人： Ratiopharm GmbH
IPC分类号： C07C211/42 , C07C53/122 , C07C53/126 , C07C57/12 , A61K31/19 , A61K31/13 , A61P25/16
CPC分类号： C07C211/42 , C07C53/122 , C07C53/126 , C07C57/12 , C07C2602/08
摘要： The present invention relates to salts of rasagiline and pharmaceutical preparations thereof. The invention further provides a method of preparing the salts of rasagiline.
摘要翻译： 本发明涉及雷沙吉兰的盐及其药物制剂。 本发明还提供了制备雷沙吉兰盐的方法。
-
公开(公告)号：EP2346846A1
公开(公告)日：2011-07-27
申请号：EP09783416.2
申请日：2009-09-25
申请人： Ratiopharm GmbH
IPC分类号： C07D333/38 , A61K31/381 , A61P19/10
CPC分类号： C07D333/40
摘要： The present invention relates to novel anhydrate and hydrate forms of strontium ranelate, processes for the preparation thereof and a pharmaceutical composition comprising said strontium ranelate.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.012 秒)
